Skip to main content
. 2022 Apr 9;12:5999. doi: 10.1038/s41598-022-10057-7

Figure 5.

Figure 5

Immune reactivity of comirnaty vaccine recipient sera against the synthetic S1P4 and S2P6 peptides. Serum samples from comirnaty vaccine recipients (n = 9) (Table S4) were collected few weeks after the receipt of the second vaccine dose. The pre-immune serum of each individual was collected prior vaccination. In (A), serum samples at dilution 1:100 have been tested for SARS-CoV-2 N and S antibodies by indirect ELISA using soluble rN and rRBD proteins for antigen-based antibody capture. The intensity values of serum samples were measured at O.D. 450 nm. Paired t tests were performed between pre-immune serum and vaccine recipient serum (ns: non-statistically significant, p > 0.05). In (B), the serum samples were assayed on the synthetic S2P4 and S2P6 peptides (200 ng.ml−1) through peptide-based ELISA at serum dilution 1:50. The synthetic S1P5 peptide served as negative control serum. The intensity values of vaccine serum samples were measured at O.D. 450 nm. Paired t tests were performed between pre-immune serum and vaccine recipient serum.